A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT06161025 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

860

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Cancer

Interventions

DRUG: R-DXd
DRUG: Paclitaxel
DRUG: Topotecan
DRUG: PLD

Sponsor

Daiichi Sankyo

Collaborators

[object Object]